Skip to main content
. 2020 Jul 10;8(7):204. doi: 10.3390/biomedicines8070204

Figure 1.

Figure 1

The design of a bispecific T cell engager antibody (BiTE). (A). Schematic representation of the derivation and structure of a BiTE molecule generated from two different antibodies, one with specificity for a T cell activation molecule and another one specific for a tumor-associated antigen (TAA). (B). Schema of a BiTE-coding gene used to produce the recombinant BiTE protein. Linkers were inserted between VH and VL domains of the single-chain fragment variable (scFv) and between the two scFvs. The linker between the two scFv is short (~5 aa) while the other linker within scFv is usually longer (~15 aa). (C). A BiTE creates an immunologic synapse by binding simultaneously to a tumor cell, via TAA, and a T cell, via CD3. This figure is modified from the Figure 1 in Slaney CY et al., Cancer Discovery, 2018 [49]. The drawings were created using BioRender (https://app.biorender.com).